High NEDA and No PIRA in Natalizumab-Treated Patients With Pediatric-Onset Multiple Sclerosis.

Marco PuthenparampilMarta GaggiolaMarta PonzanoGiovanni ZanotelliAlessandro MisciosciaMargherita NosadiniAlessandro Di PaolaStefano SartoriPaola PeriniFrancesca RinaldiFrancesca Bovis Paolo Gallo

Published in: Neurology(R) neuroimmunology & neuroinflammation (2024)

The favorable outcomes observed on clinical, especially in PIRA, and radiologic parameters strongly support the use of NTZ as a first-choice HET in POMS.

Keyphrases

multiple sclerosis
white matter
type diabetes
metabolic syndrome
insulin resistance
weight loss
glycemic control